OmniAb to Participate in Two Investor Conferences in March
04 2월 2025 - 6:57AM
Business Wire
OmniAb, Inc. (NASDAQ: OABI) today announced that
management will be participating in two investor conferences during
the month of March.
- TD Cowen 45th Annual Health Care Conference, March 3-5 at
the Boston Marriott Copley Place. Management will be presenting
a corporate overview on Tuesday, March 4th at 2:30 p.m. Eastern
time and will be holding one-on-one meetings with investors.
- 2025 Leerink Partners Global Healthcare Conference, March
9-12 at the W Hotel South Beach in Miami. Management will hold
one-on-one meetings with investors on Wednesday, March 12th.
About OmniAb® OmniAb licenses cutting edge discovery
research technology to pharmaceutical and biotech companies and
academic institutions to enable the discovery of next-generation
therapeutics. Our technology platform creates and screens diverse
antibody repertoires and is designed to quickly identify optimal
antibodies and other target-binding proteins for our partners’ drug
development efforts. At the heart of the OmniAb platform is
something we call Biological Intelligence™, which powers the immune
systems of our proprietary, engineered transgenic animals to create
optimized antibody candidates for human therapeutics. We believe
the OmniAb animals comprise the most diverse host systems available
in the industry. Our suite of technologies and methods, including
computational antigen design and immunization methods, paired with
high-throughput single B cell phenotypic screening and mining of
next-generation sequencing datasets with custom algorithms, is used
to identify fully-human antibodies with exceptional performance and
developability characteristics. We provide our partners both
integrated end-to-end capabilities and highly customizable
offerings, which address critical industry challenges and provide
optimized discovery solutions. Our business model aligns scientific
and economic interests of our partners through structured
agreements that generally include upfront/access fees, service
revenue, milestones and royalties on commercial sales.
For more information, please visit www.omniab.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250203086560/en/
OmniAb, Inc. Neha Singh, Ph.D. investors@OmniAb.com X
@OmniAbTech (510) 768-7760
OmniAb (NASDAQ:OABI)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
OmniAb (NASDAQ:OABI)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025